The novel coronavirus disease 2019 (COVID-19) is the third coronavirus outbreaks in the last two decades. Emerging and re-emerging infections like COVID-19 pose serious challenges of paucity of information and lack of specific cure or vaccines. This leaves utilisation of existing scientific data on related viral infections and repurposing relevant aetiologic and supportive therapies as the best control approach while novel strategies are developed and trialled. Many promising antiviral agents including lopinavir, ritonavir, remdesivir, umifenovir, darunavir, and oseltamivir have been repurposed and are currently trialled in the care for COVID-19 patients. Adjunct therapies for the management of symptoms and to provide support especially in severe and critically ill patients have also been identified. This review provides an appraisal of the current evidence for rational use of frontline therapeutics in the management of COVID-19. It also includes updates regarding COVID-19 immunotherapy and vaccine development. Highlights • In the absence of a definite treatment, management of COVID-19 depends on rational repurposing of drugs • Choice of pharmacologic agents for use in COVID-19 patients is based on presenting symptoms, severity and underlying conditions • Therapeutics in the management of COVID-19 can be categorised into antiviral drugs, supportive treatments and immunotherapeutic agents
